Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.

ABSTRACT:

Aim

The objective of this research is to assess the cost-effectiveness of combining camrelizumab with rivoceranib in comparison to sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma from the Chinese medical system perspective.

Methods

A partitioned survival model was employed to perform a comprehensive cost-effectiveness analysis. This analysis incorporated multiple factors, such as treatment effectiveness, adverse events and costs, all of which were derived from data obtained from the CARES-310 trial. Furthermore, sensitivity analyses were conducted to evaluate the robustness and reliability of the model.

Results

The comparison between the two groups demonstrated that the cohort receiving camrelizumab combined with rivoceranib exhibited

SUBMITTER: Cai H 

PROVIDER: S-EPMC11647293 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature